Skip to main content
. 2023 Jan 24;15(2):393. doi: 10.3390/pharmaceutics15020393

Figure 7.

Figure 7

Number of publications discussing the incorporation of first-line antitubercular drugs into nanocarriers. The search was carried out in Scopus in December 2022 using the nanocarriers described in this review as keywords. The dotted line shows the cases of multidrug-resistant/rifampicin-resistant tuberculosis (MDR/RR-TB) according to the annual reports of the World Health Organization. The drop in diagnosed cases from 2019 to 2020 is a consequence of the coronavirus pandemic.